Search Browse Earnings

Cue Biopharma, Inc.

Nasdaq:CUE

Pharmaceutical Preparations·BOSTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Cue Biopharma, Inc. — SlamSEC

Revenue

$5.5M

+341.0% YoY

FY 2024

Adj. EBITDA

-$51.6M

-939.8% margin

FY 2024

Net Income

-$50.7M

-924.1% margin

FY 2024

EPS (Diluted)

-$1.11

FY 2024

Stock Price

$0.30

+4.2%

2026-03-06

52W Range

$0.23 – $1.12

P/E Ratio

-0.3x

Market Cap

$23.6M

Cash

$48.5M

FY 2024

Total Debt

$4.2M

FY 2024

Net Cash

$44.3M

FY 2024

Enterprise Value

-$20.7M

Debt / EBITDA

0.9x

FY 2024

EV / EBITDA

0.4x

Employees

—